Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-case post-marketing surveillance of Gamifant in macrophage activation syndrome associated with Still's disease in Japan
jRCT2031260636Not yet recruiting
- Sponsor
- Sobi
- Start
- Jan 2027
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of emapalumab in macrophage activation syndrome (MAS), adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA), sponsored by Sobi. Primary endpoints: Occurrence of infections, Occurrence of infusion reactions and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
emapalumab
03
Conditions
macrophage activation syndrome (MAS)adult-onset Still's disease (AOSD)systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on jRCT2031260636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260636.